2-Deoxy-scyllo-inosose (DOI) synthase participates in the biosynthesis of 2-deoxystreptamine (DOS)-containing aminoglycoside antibiotics. The enzyme is expected to be of industrial use, because it converts a sustainable resource (glucose 6-phosphate) into carbocycle (DOI), which easily aromatizes to yield catechol. In the present study, we clarified the physiological role of a noncatalytic 20 kDa protein, BtrC2, associated with DOI synthase from the butirosin-producer Bacillus circulans. Based on the results of complementation analysis using btrC2 disruptant and western analysis against catalytic 40 kDa protein (BtrC) and BtrC2, it is suggested that BtrC2 has two functions. It is involved in the vitamin B 6 biosynthesis in primary metabolism, like homologous protein (Pdx2) in Bacillus subtilis. Additionally, it takes part in butirosin biosynthesis as stabilizer of DOI synthase by forming a heterodimer with BtrC, and qualifies B. circulans for stable and constant production of butirosin for long periods.
Because of a shortage of fossil resources and high prices, novel technology is required to prepare chemical compounds from sustainable resources. D-Glucose is one of the most notable compounds, because large amounts of it are synthesized by plants by photosynthesis. Frost et al. have found that many aromatics can be prepared from D-glucose by the use of enzymes involved in the shikimate pathway and myo-inositol synthase. [1] [2] [3] They found that catechol, an important industrial aromatic compound, can be prepared from D-glucose using recombinant Escherichia coli, but the yield of the product was very low due to its toxicity for E. coli. 4) For the industrial use, simpler and more efficient methods are required.
2-Deoxy-scyllo-inosose (DOI) synthase is a crucial and specific enzyme for the biosynthesis of 2-deoxystreptamine (DOS)-containing aminoglycoside antibiotics. It catalyzes the carbocycle-forming reaction from glucose-6-phosphate to DOI with NAD þ and Co 2þ as cofactors. Its reaction mechanism closely resembles that of 3-dehydroquinate synthase, which figures in the shikimate pathway of primary metabolism. [5] [6] [7] [8] [9] [10] [11] Many studies of the reaction mechanism, structure, and biodiversity of DOI synthase have been done because of its interesting enzymatic features. [12] [13] [14] [15] [16] [17] [18] [19] It is expected to be available for industrial use for the purposes described above. Kakinuma et al. have found that catechol can be prepared in one-pot synthesis from D-glucose using hexokinase and DOI synthase, followed by simple chemical conversion. 20) Further, Kogure et al. have succeeded in the preparation of DOI in significant amounts using metabolically engineered E. coli.
21)
DOI synthase purified from the butirosin producer Bacillus circulans consists of two proteins, BtrC (40 kDa) and BtrC2 (20 kDa). 10) BtrC is the catalytic moiety, because heterologously expressed BtrC showed enzyme activity without BtrC2. 11) Inactivation of the btrC gene in B. circulans caused inhibition of the production of butirosin. 22) Further, the butirosin-biosynthetic gene cluster has been found in the region adjacent to btrC. [22] [23] [24] These results clearly indicate that BtrC participates directly in the biosynthesis of butirosin. On the other hand, the btrC2 gene is not located in the butirosin-biosynthestic gene cluster. The gene btrC2 and orf2, located just upstream of btrC2, showed significant homology with yaaE (pdx2) and yaaD (pdx1) of Bacillus subtilis respectively. 25) Pdx1 and 2 take part in the biosynthesis of vitamin B 6 in B. subtilis as pyridoxal 5 0 -phosphate synthase. Pdx2 is a glutaminase subunit showing glutamine amidotransferase activity. Subsequently, Pdx1 synthesizes pyridoxal 5 0 -phosphate from ribose 5-phosphate, glyceraldehyde 3-phosphate, and ammonia donated from Pdx2. [26] [27] [28] The B. circulans btrC2 disruptant showed deficiencies in both growth and antibiotic production, although the addition of pyridoxine did not restore the growth. 25) On the other hand, BtrC y To whom correspondence should be addressed. Fax: +81-3-5317-9433; E-mail: htamegai@chs.nihon-u.ac.jp expressed in E. coli is more labile than heterodimer BtrC-BtrC2 purified from B. circulans or co-expressed in E. coli. 11) These observations suggest that BtrC2 plays roles both in primary and in secondary metabolism, but the detailed properties of BtrC2 in B. circulans are still unknown. Demonstration of the properties of a useful enzyme like DOI synthase is meaningful for application to industry.
In the present study, we investigated the physiological properties of BtrC2 by experiments on growth properties of B. circulans and western blot. The roles of BtrC2 in both primary and secondary metabolism are discussed.
Materials and Methods
Organisms. B. circulans SANK 72073 (wild type), 4-41 (btrC2 disruptant), 25) btrC disruptant, 22) and 4-41 carrying a plasmid for gene complementation were cultured in a butirosin-producing medium as described previously 10) or in a glucose minimal medium 29) at 28 C with shaking (150 rpm, reciprocation). The media were supplemented with 10 mg/ml of pyridoxal-HCl or pyridoxine-HCl when necessary. For accurate estimation of doubling time, three independent experiments were carried out. E. coli DH5 and BL21(DE3) were cultured in LB medium or on LB-agar containing 50 mg/ml of ampicilin or 30 mg/ml of kanamycin when necessary.
Gene complementation of the btrC2 disruptrant. In the construction of btrC2-expression vector in B. circulans, oligonucleotides btrC2SD-f (GAGCTCGGACCGCGGCTGGTAATCGGC, starting 45 bases upstream from the start codon of btrC2, Sac I site added at the 5 0 end) and btrC2SD-r (GGATCCTCAACGGGCTTCCCGGATCATA, starting with the stop codon of btrC2, BamH I site added at the 5 0 end) were designed as PCR primers. PCR reaction was carried out with genomic DNA extracted from B. circulans as template for amplification of the full length of btrC2, including its ribosomal binding site. The program was as follows: 1 cycle at 95 C for 10 min, followed by 30 cycles of 95 C for 1 min, 60 C for 1 min, and 72 C for 1 min, and then 72 C for 10 min. The PCR product was subcloned into pT7-blue T vector (Novagen, San Diego, California, USA) to yield pT7btrC2SD. After confirmation of the sequence, the Sac I-BamH I fragment carrying the full length of btrC2 with its ribosomal binding site was recovered from pT7btrC2SD and subcloned into the corresponding site of pHB201 22, 30) to yield pHBbtrC2SD. Plasmid pHB201 has a region of promoter 59 upstream of the multi-cloning site, which allows gene expression in Bacilli, 31) including B. circulans. 32) The resulting plasmid for complementation of btrC2 disruption was introduced into B. circulans 4-41 by electropolation. 22) Expression of BtrC2 in E. coli. Oligonucleotides 20k-f (CATA-TGAAAGTTGGCGTATTGGC starting with the start codon of btrC2, Nde I site added at the 5 0 end) and 20k-r (CTCGAGTCAACGGG-CTTCCCGGATCA starting with the stop codon of btrC2, Xho I site added at the 5 0 end) were designed as PCR primers. PCR reaction was carried out using these primers, with genomic DNA extracted from B. circulans as template. The program was as follows: 1 cycle at 95 C for 10 min, followed by 30 cycles of 95 C for 1 min, 57 C for 1 min, and 72 C for 1 min, and then 72 C for 10 min. The PCR product was subcloned into pT7-blue T vector to yield pT7btrC2. After confirmation of the sequence, the Nde I-Xho I fragment was recovered from pT7btrC2 and subcloned into the corresponding site of pET19b (Novagen) to yield pETbtrC2 carrying the full length of btrC2 fused with the sequence for His-tag at the 5 0 end. E. coli BL21(DE3) carrying pETbtrC2 was cultivated in 50 ml of LB medium containing 50 mg/ml of ampicilin until OD 600 reached 0.6-1.0, and then isopropyl--D-thiogalactopyranoside was added to a final concentration of 1 mM. After 2 h of additional cultivation, cells were harvested by centrifugation (8;000 Â g, 5 min), and were stocked at À80 C until use.
Preparation of antisera against BtrC and BtrC2. BtrC was expressed in E. coli BL21(DE3) carrying pDS4, and purified as described previously.
11) Antiserum against BtrC was prepared by Takara Bio (Otsu, Shiga, Japan) with rabbit. In the case of BtrC2, a large amount of the protein was expressed as an inclusion body as judged by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE). Hence the inclusion body was solubilized by urea. Subsequently BtrC2 was purified by His-trap column chromatography (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and recovery from SDS-PAGE, as described previously. 33) Antiserum against BtrC2 was prepared by BioGate (Yamagata, Gifu, Japan) with rabbit.
Western blot analysis. The various strains of B. circulans were cultivated in 50 ml of butirosin-producing medium (supplemented with 10 mg/ml of pyridoxal-HCl when necessary) for various cultivation times. Cells at different growth phases were harvested by centrifugation (8;000 Â g, 5 min) and stocked at À25 C until use. The frozen cells were thawed, suspended in 10 mM Tris-HCl buffer pH 8, and disrupted with a sonic oscillator for a total period of 15 min. Unbroken cells were removed by centrifugation (8;000 Â g, 5 min) and the resulting supernatant was used as the cell-free extract. Each cell-free extract was loaded on SDS-PAGE, subsequently blotted to a polyvinyliden difluoride membrane, and hybridized with antiserum (1:10,000 for each antiserum). One mg of protein was loaded on each lane for SDS-PAGE for detection of BtrC, and 10 mg for BtrC2. Detection was carried out using an ECL Plus kit (GE Healthcare BioSciences, Piscataway, New Jersey, USA), as described previously.
33)
Analysis of antibiotic activity. B. circulans were cultured in 50 ml of butirosin-producing medium for various cultivation times. After 50 h of cultivation, the culture was centrifuged (8;000 Â g, 5 min) and the supernatant was removed. The cells obtained were resuspended with 50 ml of fresh butirosin-producing medium, and were subjected to further incubation at 28 C with shaking for 25 h. For the second incubation of 4-41, 10 mg/ml of pyridoxal-HCl was added to the medium. For analysis of antibiotic activity, the culture was centrifuged (10;000 Â g, 5 min), and the supernatant was subjected to antibiotic assay by the paper disk diffusion method.
34)
Molecular biological and biochemical procedures. DNA manipulations were performed as described in the literature. 35) Extraction of genomic DNA was carried out with Dr. Gentle (Takara Bio). DNA sequencing was carried out by Bio Matrix Research (Nagareyama, Chiba, Japan). PCR was performed with MyCycler (Bio-Rad, Hercules, California, USA) using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, California, USA). Oligo DNA fragments for PCR primers were synthesized by Sigma Genosys (Ishikari, Hokkaido, Japan). Purification of plasmids was carried out with a illustra plasmidPrep Mini Spin Kit (GE Healthcare Bio-Sciences UK, Littele Chalfont, Buckinghamshire, UK). Restriction enzymes and modification enzymes were purchased from Takara Bio. The protein concentration was determined by the method of Lowry et al., 36) with slight modifications. 37) SDS-PAGE was performed by the method of Laemmli.
38)

Results
Growth of B. circulans under various conditions
The doubling times for the growth of B. circulans under various conditions were determined, and are summarized in Fig. 1 . In glucose minimal medium, 4-41 (the btrC2 disruptant) showed no significant growth within a period of 60 h, which is consistent with our previous results.
25 ) The addition of 10 mg/ml of pyridoxal or complementation with btrC2 from B. circulans completely restored growth. The addition of pyridoxine was less effective than that of pyridoxal. In butirosinproducing medium, the growth of 4-41 was significantly slower than that of the wild type. As was the case for the minimal medium, the addition of pyridoxal or gene complementation restored growth. The addition of pyridoxine showed almost no contribution to the butirosin-producing medium.
Expression of BtrC and BtrC2 in B. circulans Preparation of antisera against BtrC and BtrC2 was confirmed by western blot using purified proteins and cell-free extracts of the B. circulans wild type and the btrC disruptant. In the detection of BtrC, two bands were observed, as shown in Fig. 2Aa-d . It was confirmed that the lower band corresponded to BtrC by comparison of the B. circulans wild type and the btrC disruptant (data not shown). Growth phase-dependent expression of BtrC and BtrC2 in B. circulans SANK 72073 (the wild type) was determined by western blot using cell-free extract of the bacterium and the prepared antisera. As shown in Fig. 2Aa , expression of BtrC was initiated after 15 h of cultivation (the late exponential phase), and strongly was induced at 20-25 h of cultivation (the early stationary phase). On the other hand, BtrC2 was constitutively expressed independently of the cultivation time (Fig. 2Aa  0 ) . In the case of B. circulans 4-41, BtrC was also expressed after 25 h of cultivation (the late exponential phase), as shown in Fig. 2Ab . The difference in cultivation time between the two strains was due to the slow growth of the mutant, as shown in Fig. 2B . The slow growth of 4-41 was clear. The growth curves of 4-41 supplemented with pyridoxal and 4-41 carrying pHBbtrC2SD showed almost same pattern as the wild type. However, inconsistently with the case of the wild type, the amount of BtrC was significantly decreased at a cultivation time of 50 h. BtrC expression in growth-and antibiotic production-restored B. circulans 4-41 was also examined (Fig. 2Ac and d) . BtrC expression was started at a cultivation time of 15 h (the late exponential phase) in both cases. In B. circulans 4-41/ pHBbtrC2SD, a significant amount of BtrC was still observed at 50 h of cultivation (Fig. 2Ad) . On the other hand, the amount of BtrC was drastically decreased in 4-41 supplemented with 10 mg/ml of pyridoxal (Fig. 2Ac) at a cultivation time of 50 h.
Antibiotic production of B. circulans under various conditions
The production of antibiotic was determined under each culture condition. In agreement with the previous results, 25) 4-41 showed no antibiotic activity. During the first 50 h of cultivation, the addition of pyridoxal or gene complementation restored antibiotic activity, while the addition of pyridoxine did not (Fig. 3, top) . In all antibiotic-producing cultivation, antibiotic activity was evident after 24-27 h of cultivation, corresponding to the early stage of the stationary phase. The wild type and 4-41 carrying pHBbtrC2SD showed antibiotic activity on further incubation with fresh butirosin-producing medium, but 4-41 showed no further activity even though enough pyridoxal (10 mg/ml) was fed (Fig. 3,  bottom) . Even under this condition, the viability of 4-41 appeared not to change, because 4-41 grew when it was seeded on agar medium or in liquid medium after 50 h of cultivation.
Discussion
Here we studied the detailed properties of BtrC2 (a 20 kDa protein associated with DOI synthase) in B. circulans by comparing the features between the wild type and the btrC2 disruptant. Deficiency in the growth of the btrC2 disruptant ( Fig. 1) clearly indicated that BtrC2 plays a role in primary metabolism, as suggested in a previous study.
25 ) The results of western analyses also confirmed this hypothesis. BtrC2 was expressed in the B. circulans wild type even in the middle of the exponential phase (Fig. 2Aa 0 ), although BtrC was significantly induced at the late exponential phase (Fig. 2Aa) and antibiotic activity was evident in the stationary phase. Further, complementation of growth due to the addition of pyridoxal indicates that BtrC2 participates in vitamin B 6 biosynthesis as is the case for Pdx2 in B. subtilis. 26) Pyridoxine is less effective than pyridoxal for recovery of the growth. This is probably due to the capacity for uptake of pyridoxine, which is consistent with the case of the pdx1 disruptant of B. subtilis. 27) In our previous study, we concluded that the addition of pyridoxine did not restore the growth of the B. circulans btrC2 disruptant. 25) However, in the minimal medium, a slight increase in the optical density of the culture was observed under supplementation with pyridoxine ( Fig. 5A in reference  25) . At that time, we thought that this was caused by experimental error. In this study, we concluded that our previous conclusion was incorrect. Pyridoxine was effective for recovery of the growth of the btrC2 disruptant, even though it was considerably less effective than pyridoxal.
The B. circulans btrC2 disruptant showed no antibiotic activity (Fig. 3b) , but BtrC was expressed even in the btrC2 disruptant (Fig. 2Ab) . Possibly other butirosin-biosynthetic enzymes were also expressed in the disruptant, because the genes encoding BtrC and these enzymes are located in the same operon. [22] [23] [24] This hypothesis does not conflict with the previous finding that btrC and btrC2 are located in different operons. 25) Additionally, feeding of pyridoxal to the btrC2 disruptant resulted in recovery of antibiotic activity in the first 50 h of cultivation (Fig. 3c, top) . This suggests that the loss of antibiotic production in btrC2 disruptant in the first 50 h of cultivation was due to a deficiency of pyridoxal, which is an important cofactor for the reaction of butirosin-biosynthetic aminotransferase BtrS. 23, 39) However, the amount of BtrC decreased significantly in the btrC2 disruptant at the stationary phase (Fig. 2Ab) . Further, the btrC2 disruptant showed no antibiotic activity in 25 h of additional incubation with fresh butirosin-producing medium supplemented with pyridoxal, even though it produced antibiotics in the first 50 h of cultivation under feeding of pyridoxal ( Fig. 3b and c) . These findings indicate that the antibiotic producing activity of the btrC2 disruptant was lost after a cultivation time of 50 h due to the decrease in BtrC, which is crucial for butirosin biosynthesis. Only gene complementation by btrC2 suppressed the decrease in BtrC (Fig. 2Ad ) and antibiotic production (Fig. 3d) . These results suggest that BtrC2 binds specifically with BtrC to stabilize the enzyme not only in vitro 25) but also in vivo. That is to say, DOI synthase can exist in the cell of B. circulans stably and can contribute to butirosin biosynthesis over a long period.
It is suggested that BtrC2 has two functions. In primary metabolism, it plays a role in vitamin B 6 biosynthesis, perhaps like Pdx2 in B. subtilis. Further, it stabilizes DOI synthase by forming a heterodimer with BtrC in vivo too, and enables B. circulans to show stable and constant production of butirosin for long periods. 
